Cargando…
Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial
BACKGROUND: To evaluate the effects of the lactic acid bacterium Lactobacillus salivarius on caries risk factors. METHODS: The study was performed in 64 healthy volunteers to evaluate the effects of L. salivarius-containing tablets on caries risk factors. The participants were divided randomly into...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236677/ https://www.ncbi.nlm.nih.gov/pubmed/25178882 http://dx.doi.org/10.1186/1472-6831-14-110 |
_version_ | 1782345216783548416 |
---|---|
author | Nishihara, Tetsuyo Suzuki, Nao Yoneda, Masahiro Hirofuji, Takao |
author_facet | Nishihara, Tetsuyo Suzuki, Nao Yoneda, Masahiro Hirofuji, Takao |
author_sort | Nishihara, Tetsuyo |
collection | PubMed |
description | BACKGROUND: To evaluate the effects of the lactic acid bacterium Lactobacillus salivarius on caries risk factors. METHODS: The study was performed in 64 healthy volunteers to evaluate the effects of L. salivarius-containing tablets on caries risk factors. The participants were divided randomly into four groups, and took tablets containing L. salivarius WB21, L. salivarius TI 2711, Ovalgen® DC (antibody against glucosyltransferase from Streptococcus mutans), or xylitol. Levels of mutans streptococci and lactobacilli, amount of salivary flow, salivary pH, and salivary buffering capacity were assessed before and after taking the tablets. Subsequently, a short-term administration trial using L. salivarius WB21-containing tablets was performed in eight healthy volunteers. The participants took L. salivarius WB21-containing tablets (2.0 × 10(9) colony forming units/day) for 2 weeks, and the numbers of mutans streptococci in saliva were counted. RESULTS: The levels of mutans streptococci seemed to decrease in the L. salivarius WB21, TI 2711, and Ovalgen® DC groups compared to the xylitol group, with no significant differences between the groups. Lactobacilli levels significantly increased in the L. salivarius WB21 and TI 2711 groups compared to the other groups. Concerning salivary flow and salivary pH, no significant differences were observed between the groups. The salivary buffering capacity significantly increased in the L. salivarius TI 2711 group (P = 0.003) and Ovalgen® DC group (P = 0.002) compared to the xylitol group. The short-term administration trial showed that the L. salivarius WB21-containing tablets significantly decreased the number of mutans streptococci (P = 0.039). CONCLUSION: L. salivarius-containing tablets were suggested to increase resistance to caries risk factors. TRIAL REGISTRATION: UMIN000013160 (registration date: February 14, 2014). |
format | Online Article Text |
id | pubmed-4236677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42366772014-11-20 Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial Nishihara, Tetsuyo Suzuki, Nao Yoneda, Masahiro Hirofuji, Takao BMC Oral Health Research Article BACKGROUND: To evaluate the effects of the lactic acid bacterium Lactobacillus salivarius on caries risk factors. METHODS: The study was performed in 64 healthy volunteers to evaluate the effects of L. salivarius-containing tablets on caries risk factors. The participants were divided randomly into four groups, and took tablets containing L. salivarius WB21, L. salivarius TI 2711, Ovalgen® DC (antibody against glucosyltransferase from Streptococcus mutans), or xylitol. Levels of mutans streptococci and lactobacilli, amount of salivary flow, salivary pH, and salivary buffering capacity were assessed before and after taking the tablets. Subsequently, a short-term administration trial using L. salivarius WB21-containing tablets was performed in eight healthy volunteers. The participants took L. salivarius WB21-containing tablets (2.0 × 10(9) colony forming units/day) for 2 weeks, and the numbers of mutans streptococci in saliva were counted. RESULTS: The levels of mutans streptococci seemed to decrease in the L. salivarius WB21, TI 2711, and Ovalgen® DC groups compared to the xylitol group, with no significant differences between the groups. Lactobacilli levels significantly increased in the L. salivarius WB21 and TI 2711 groups compared to the other groups. Concerning salivary flow and salivary pH, no significant differences were observed between the groups. The salivary buffering capacity significantly increased in the L. salivarius TI 2711 group (P = 0.003) and Ovalgen® DC group (P = 0.002) compared to the xylitol group. The short-term administration trial showed that the L. salivarius WB21-containing tablets significantly decreased the number of mutans streptococci (P = 0.039). CONCLUSION: L. salivarius-containing tablets were suggested to increase resistance to caries risk factors. TRIAL REGISTRATION: UMIN000013160 (registration date: February 14, 2014). BioMed Central 2014-09-02 /pmc/articles/PMC4236677/ /pubmed/25178882 http://dx.doi.org/10.1186/1472-6831-14-110 Text en Copyright © 2014 Nishihara et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Nishihara, Tetsuyo Suzuki, Nao Yoneda, Masahiro Hirofuji, Takao Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial |
title | Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial |
title_full | Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial |
title_fullStr | Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial |
title_full_unstemmed | Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial |
title_short | Effects of Lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial |
title_sort | effects of lactobacillus salivarius-containing tablets on caries risk factors: a randomized open-label clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236677/ https://www.ncbi.nlm.nih.gov/pubmed/25178882 http://dx.doi.org/10.1186/1472-6831-14-110 |
work_keys_str_mv | AT nishiharatetsuyo effectsoflactobacillussalivariuscontainingtabletsoncariesriskfactorsarandomizedopenlabelclinicaltrial AT suzukinao effectsoflactobacillussalivariuscontainingtabletsoncariesriskfactorsarandomizedopenlabelclinicaltrial AT yonedamasahiro effectsoflactobacillussalivariuscontainingtabletsoncariesriskfactorsarandomizedopenlabelclinicaltrial AT hirofujitakao effectsoflactobacillussalivariuscontainingtabletsoncariesriskfactorsarandomizedopenlabelclinicaltrial |